NIH-FUNDED STUDY FINDS EARLY HAART DURING TB TREATMENT BOOSTS SURVIVAL RATE IN PEOPLE CO-INFECTED WITH HIV AND TB
July 22, 2010 - A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very
weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting
eight weeks, as has been standard. This finding by scientists co-funded by the National Institute of Allergy and Infectious Diseases (NIAID),
part of the National Institutes of Health, and the French National Agency for Research on AIDS and Viral Hepatitis, brings physicians
closer to optimizing the treatment of severely immunosuppressed individuals with HIV-TB co-infection. The findings were presented
today at the XVIII International AIDS Conference in Vienna by principal investigators Francois-Xavier Blanc, M.D., Anne E. Goldfeld, M.D., and Sok Thim, M.D.
"These results are just one example of how our best science can advance the treatment of an important disease, TB, that exacts a huge toll among HIV-infected
individuals," says NIAID Director Anthony S. Fauci, M.D. "With an estimated 1.4 million HIV-infected individuals developing TB in 2008 alone, we must
continue to pursue 21st-century solutions to the scourge of HIV-TB co-infection, as well as other diseases that afflict HIV-infected people."
Individuals with HIV-TB co-infection in resource-limited countries frequently come to the attention of healthcare professionals for the first time when HIV already
has severely damaged their immune systems. Such people often die during the first few months after beginning TB treatment. Clinicians agree that starting anti-HIV
therapy during that short window can stave off death for some patients, but data on the best time to start have proven inconclusive and opinions have varied.
The dilemma is that starting anti-HIV therapy before the TB infection is under control can cause the patient to become very sick and even die from a
condition known as Immune Reconstitution Inflammatory Syndrome, but starting anti-HIV therapy too late may allow the patient to die from HIV
infection. TB accounted for nearly a quarter of HIV-related deaths worldwide in 2008.
The clinical trial, called the Cambodian Early versus Late Introduction of Antiretroviral Drugs (CAMELIA), or ANRS 1295, launched in January 2006 at five sites in Cambodia,
a country with a high prevalence of TB and HIV. The study staff enrolled 661 volunteers ages 18 and older with newly diagnosed HIV-TB co-infection and very weak immune
systems (measured as fewer than 200 CD4+ T cells per cubic millimeter of blood). The participants all began receiving treatment for TB and were assigned at random
to begin antiretroviral therapy for HIV either two weeks later or eight weeks later. The volunteers received powerful antiretroviral drug cocktails known as
highly active antiretroviral therapy, or HAART. Study staff followed the participants for 50 weeks after the last volunteer had enrolled in the trial,
performing clinical exams and biological tests at frequent intervals to monitor participants' health and safety.
By the end of the follow-up period, 59 out of 332 participants who had started HAART two weeks after beginning TB treatment had died, while 90 out of 329 participants
who started HAART eight weeks after beginning TB treatment had died. This 33 percent difference was statistically significant, leading the principal investigators to
conclude that starting HAART two weeks after beginning TB treatment, rather than waiting eight weeks, boosts the chance of survival for people with HIV-TB
co-infection and severely damaged immune systems.
CAMELIA was conducted within the research agenda of the Cambodian National Center for HIV/AIDS, Dermatology and STD under the leadership of Dr. Blanc of Bicetre
University Hospital, France; Dr. Goldfeld of Harvard Medical School, Boston; and Dr. Sok of the Cambodian Health Committee, Phnom Penh. NIAID provided funding
for the study to the Cambodian Health Committee via a grant from the Comprehensive International Program for Research on AIDS.
For more information about CAMELIA, please see Questions and Answers: The CAMELIA Clinical Trial http://www.niaid.nih.gov/news/QA/Pages/CAMELIAqa.aspx .
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to
study the causes of infectious and immune-mediated diseases, and to develop
better means of preventing, diagnosing and treating these illnesses. News releases,
fact sheets and other NIAID-related materials are available on the NIAID Web
site at http://www.niaid.nih.gov.
The National Institutes of Health (NIH) — The Nation's
Medical Research Agency — includes 27 Institutes and
Centers and is a component of the U.S. Department of Health and
Human Services. It is the primary federal agency for conducting
and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments, and cures for both
common and rare diseases. For more information about NIH and
its programs, visit www.nih.gov.
Laura Sivitz Leifman
Source: NIH News: National Institutes of Health